About   Help   FAQ
References
Query Results -- Details

MGI Accession ID: MGI:3574690
J Number: J:97163
Other Accession IDs: Title: Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
Authors: Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
Journal: Cancer Res
Volume: 65
Issue: 6
Date: 2005 Mar 15
Year: 2005
Pages: 2287-95
Review Status: Peer Reviewed

Abstract:

Hormone-refractory relapse is an inevitable and lethal event for advanced prostate cancer patients after hormone deprivation. A growing body of evidence indicates that hormone deprivation may promote this aggressive prostate cancer phenotype. Notably, androgen receptor (AR) not only mediates the effect of androgen on the tumor initiation but also plays the major role in the relapse transition. This provides a strong rationale for searching new effective agents targeting the down-regulation of AR to treat or prevent advanced prostate cancer progression. Here, we show that emodin, a natural compound, can directly target AR to suppress prostate cancer cell growth in vitro and prolong the survival of C3(1)/SV40 transgenic mice in vivo. Emodin treatment resulted in repressing androgen-dependent transactivation of AR by inhibiting AR nuclear translocation. Emodin decreased the association of AR and heat shock protein 90 and increased the association of AR and MDM2, which in turn induces AR degradation through proteasome-mediated pathway in a ligand-independent manner. Our work indicates a new mechanism for the emodin-mediated anticancer effect and justifies further investigation of emodin as a therapeutic and preventive agent for prostate cancer.

Additional Information:

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/20/2009
MGI_4.31
Web browser compatibility
The Jackson Laboratory